Maxillary carcinosarcoma: Identification of a novel MET mutation in both carcinomatous and sarcomatous components through next generation sequencing

被引:11
作者
Ando, Mizuo [1 ]
Saito, Yuki [1 ]
Morikawa, Teppei [2 ]
Omura, Go [1 ]
Kobayashi, Kenya [1 ]
Akashi, Ken [1 ]
Yoshida, Masafumi [1 ]
Ebihara, Yasuhiro [1 ]
Fujimoto, Chisato [1 ]
Fukayama, Masashi [2 ]
Yamasoba, Tatsuya [1 ]
Asakage, Takahiro [1 ]
机构
[1] Tokyo Univ Hosp, Dept Otolaryngol Head & Neck Surg, Tokyo 1138655, Japan
[2] Tokyo Univ Hosp, Dept Pathol, Tokyo 1138655, Japan
来源
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK | 2015年 / 37卷 / 12期
关键词
carcinosarcoma; papilloma; malignant transformation; MET mutation; c-MET inhibitor; CELL LUNG-CANCER; C-MET; TYROSINE KINASE; POLYMORPHIC VARIANTS; HUMAN-PAPILLOMAVIRUS; RECEPTOR; GROWTH; DOMAIN; PROTOONCOGENE; TUMORS;
D O I
10.1002/hed.24043
中图分类号
R76 [耳鼻咽喉科学];
学科分类号
100213 ;
摘要
Background. Carcinosarcoma is a rare tumor with biphasic growth of the carcinomatous and sarcomatous components. Prognosis is generally poor and characterization of the molecular mechanisms may provide information for the development of novel antitumor agents and biomarkers. Methods and Results. We present the case of 66-year-old man with a complaint of nasal obstruction. He was diagnosed with maxillary carcinosarcoma and coexisting papilloma. He underwent multimodal treatment but died of uncontrolled local disease 10 months after the initial presentation. Genetic testing using next-generation sequencing (NGS) revealed that both the carcinomatous and sarcomatous components carried a somatic mutation in the conserved domain of the mesenchymal-epithelial transition factor (MET) proto-oncogene. Conclusion. Our observation highlighted the importance of the MET gene in the oncogenesis of maxillary carcinosarcoma and is indicative of the common clonal origin of both malignant components. This suggested a possibility of treating MET mutation-positive carcinosarcomas with c-MET inhibitors. (C) 2015 Wiley Periodicals, Inc.
引用
收藏
页码:E179 / E185
页数:7
相关论文
共 46 条
[1]   A method and server for predicting damaging missense mutations [J].
Adzhubei, Ivan A. ;
Schmidt, Steffen ;
Peshkin, Leonid ;
Ramensky, Vasily E. ;
Gerasimova, Anna ;
Bork, Peer ;
Kondrashov, Alexey S. ;
Sunyaev, Shamil R. .
NATURE METHODS, 2010, 7 (04) :248-249
[2]   TP53 mutational analysis supports monoclonal origin of biphasic sarcomatoid urothelial carcinoma (carcinosarcoma) of the urinary bladder [J].
Armstrong, Andrew B. ;
Wang, Mingsheng ;
Eble, John N. ;
MacLennan, Gregory T. ;
Montironi, Rodolfo ;
Tan, Puay-Hoon ;
Lopez-Beltran, Antonio ;
Zhang, Shaobo ;
Baldridge, Lee Ann ;
Spartz, Helena ;
Cheng, Liang .
MODERN PATHOLOGY, 2009, 22 (01) :113-118
[3]   Oncogene alterations in endometrial carcinosarcomas [J].
Biscuola, Michele ;
Van de Vijver, Koen ;
Angeles Castilla, Maria ;
Romero-Perez, Laura ;
Angeles Lopez-Garcia, Maria ;
Diaz-Martin, Juan ;
Matias-Guiu, Xavier ;
Oliva, Esther ;
Palacios Calvo, Jose .
HUMAN PATHOLOGY, 2013, 44 (05) :852-859
[4]   Opinion -: Invasive growth:: a MET-driven genetic programme for cancer and stem cells [J].
Boccaccio, Carla ;
Comoglio, Paolo M. .
NATURE REVIEWS CANCER, 2006, 6 (08) :637-645
[5]   IDENTIFICATION OF THE HEPATOCYTE GROWTH-FACTOR RECEPTOR AS THE C-MET PROTOONCOGENE PRODUCT [J].
BOTTARO, DP ;
RUBIN, JS ;
FALETTO, DL ;
CHAN, AML ;
KMIECIK, TE ;
VANDEWOUDE, GF ;
AARONSON, SA .
SCIENCE, 1991, 251 (4995) :802-804
[6]   Phase II and Biomarker Study of the Dual MET/VEGFR2 Inhibitor Foretinib in Patients With Papillary Renal Cell Carcinoma [J].
Choueiri, Toni K. ;
Vaishampayan, Ulka ;
Rosenberg, Jonathan E. ;
Logan, Theodore F. ;
Harzstark, Andrea L. ;
Bukowski, Ronald M. ;
Rini, Brian I. ;
Srinivas, Sandy ;
Stein, Mark N. ;
Adams, Laurel M. ;
Ottesen, Lone H. ;
Laubscher, Kevin H. ;
Sherman, Laurie ;
McDermott, David F. ;
Haas, Naomi B. ;
Flaherty, Keith T. ;
Ross, Robert ;
Eisenberg, Peter ;
Meltzer, Paul S. ;
Merino, Maria J. ;
Bottaro, Donald P. ;
Linehan, W. Marston ;
Srinivasan, Ramaprasad .
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (02) :181-186
[7]   c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention [J].
Christensen, JG ;
Burrows, J ;
Salgia, R .
CANCER LETTERS, 2005, 225 (01) :1-26
[8]  
Danilkovitch-Miagkova A, 2002, J CLIN INVEST, V109, P863
[9]   The codon 72 polymorphic variants of p53 have markedly different apoptotic potential [J].
Dumont, P ;
Leu, JIJ ;
Della Pietra, AC ;
George, DL ;
Murphy, M .
NATURE GENETICS, 2003, 33 (03) :357-365
[10]   Novel Therapeutic Inhibitors of the c-Met Signaling Pathway in Cancer [J].
Eder, Joseph Paul ;
Woude, George F. Vande ;
Boerner, Scott A. ;
LoRusso, Patricia M. .
CLINICAL CANCER RESEARCH, 2009, 15 (07) :2207-2214